Methods of treating pre-eclampsia and eclampsia

Details Methods of treating pre-eclampsia and eclampsia Methods of treating pre-eclampsia and eclampsia

2008-02-12

2010-12-07

Landsman, Robert (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C435S007100, C435S007200, C514S002600, C514S012200, C530S387100, C530S388200

Reexamination Certificate

active

07846433

ABSTRACT:
Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia. Also disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1—are also disclosed herein for the treatment of pre-eclampsia or eclampsia.

REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5238819 (1993-08-01), Roberts et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5543138 (1996-08-01), Keith
patent: 5712395 (1998-01-01), App et al.
patent: 5763441 (1998-06-01), App et al.
patent: 5830879 (1998-11-01), Isner
patent: 5958715 (1999-09-01), Muller
patent: 6100071 (2000-08-01), Davis-Smyth et al.
patent: 6258787 (2001-07-01), Isner
patent: 6365157 (2002-04-01), Rockwell et al.
patent: 6399585 (2002-06-01), Larson et al.
patent: 6410322 (2002-06-01), Robinson
patent: 6447768 (2002-09-01), Van Zonneveld et al.
patent: 6660534 (2003-12-01), McVicker et al.
patent: 6677300 (2004-01-01), Schreiner et al.
patent: 7030083 (2006-04-01), Schreiner et al.
patent: 7335362 (2008-02-01), Karumanchi et al.
patent: 7407659 (2008-08-01), Karumanchi et al.
patent: 7435419 (2008-10-01), Karumanchi et al.
patent: 7727733 (2010-06-01), Buhimschi et al.
patent: 2003/0114412 (2003-06-01), Ward et al.
patent: 2003/0144298 (2003-07-01), Curwen et al.
patent: 2003/0220262 (2003-11-01), Schreiner et al.
patent: 2004/0038305 (2004-02-01), Poston et al.
patent: 2004/0126828 (2004-07-01), Karumanchi et al.
patent: 2005/0025762 (2005-02-01), Karumanchi et al.
patent: 2005/0148023 (2005-07-01), Thadhani et al.
patent: 2005/0148040 (2005-07-01), Thadhani et al.
patent: 2005/0170444 (2005-08-01), Karumanchi et al.
patent: 2006/0183175 (2006-08-01), Buhimschi et al.
patent: 1417971 (2004-05-01), None
patent: WO98/28006 (1998-07-01), None
patent: WO02/37120 (2002-05-01), None
patent: WO2006/069373 (2006-06-01), None
U.S. Appl. No. 10/920,116, filed Aug. 16, 2004, Thadhani et al. (Pending Application).
U.S. Appl. No. 10/947,791, filed Sep. 23, 2004, Thadhani et al. (Pending Application).
Aggarwal et al., “Low Urinary Placental Growth Factor is a Marker of Preeclampsia,”Kidney Int. 69(3): 621-624 (2006).
Ahmed et al., “Regulation of Placental Vascular Endothelial Growth Factor (VEGF) and Placenta Growth Factor (PIGF) and Soluble Flt-1 by Oxygen-A Review,”Placenta21:S16-S24 (2000).
Baek et al., Hypoxia-Induced VEGF Enhances Tumor Survivability via Suppression of Serum Deprivation-Induced Apoptosis.Oncogene19:4621-4631 (2000).
Baker et al., “Elevated Serum Levels of Vascular Endothelial Growth Factor in Patients with Preeclampsia,”Obstet. Gynocol. 86: 815-821 (1995).
Barleon et al., “Soluble VEGFR-1 Secreted by Endothelial Cells and Monocytes is Present in Human Serum and Plasma from Healthy Donors,”Angiogenesis4:143-154 (2001).
Baumgartner et al., “Constitutive Expression of ph VEGF165After Intramuscular Gene Transfer Promotes Collateral Vessel Development in Patients with Critical Limb Ischemia,”Circulation97:1114-1123 (1998).
Baumwell et al., “Preeclampsia: Clinical Manifestations and Molecular Mechanisms,”Nephron. Clin. Pract. 106(2): c72-81 (2007).
Bdolah et al., “Angiogenic Imbalance in the Pathophysiology of Preeclamsia: Newer Insights,”Semin. Nephrol. 24(6): 548-556 (2004).
Bdolah et al., “Recent Advances in Understanding of Preeclampsia,”Croat. Med. J. 46(5): 728-736 (2005).
Belgore et al., “Measurement of Free and Complexed Soluble Vascular Endothelial Growth Factor Receptor, Flt-1, in Fluid Samples: Development and Application of Two New Immunoassays,”Clin. Sci. 100:567-575 (2001).
Belgore et al., “Plasma Levels of Vascular Endothelial Growth Factor and its Soluble Receptor (SFlt-1) in Essential Hypertension,”Am. J. Cardiol. 87:805-807 (2001).
Belgore et al., “sFlt-1, a Potential Antagonist for Exogenous VEGF,”Circulation102:E108-109 (2000).
Belgore et al., “Successful Therapy Reduces Levels of Vascular Endothelial Growth Factor (VEGF) in Patients with Hypertension and Patients with Hypercholesterolemia,”Atherosclerosis151: 599 (2000).
Belgore et al., “Vascular Endothelial Growth Factor and its Receptor, Flt-1, in Smokers and Non-Smokers,”Br. J. Biomed. Sci. 57: 207-213 (2000).
Blann et al., “Plasma Vascular Endothelial Growth Factor and its Receptor Flt-1 in Patients with Hyperlipidemia and Atherosclerosis and the Effects of Fluvastatin or Fenofibrate,”Am. J. Cardiol. 87: 1160-1163 (2001).
Bolte et al., “Management and Monitoring of Severe Preeclampsia,”Eur. J. Obstet. Gynecol. Reprod. Biol. 96: 8-20 (2001).
Bouletreau et al., “Hypoxia and VEGF Up-Regulate BMP-2 mRNA and Protein Expression in Microvascular Endothelial Cells: Implications for Fracture Healing,”Plast. Reconstr. Surg. 109: 2384-2397 (2002).
Brockelsby et al., “VEGF Via VEGF Receptor-1 (Flt-1) Mimics Preeclamptic Plasma in Inhibiting Uterine Blood Vessel Relaxation in Pregnancy: Implications in the Pathogenesis of Preeclampsia,”Lab. lnvest.79: 1101-1111 (1999).
Brown et al., “Vascular Permeability Factor mRNA and Protein Expression in Human Kidney,”Kidney Int. 42: 1457-1461 (1992).
Carmeliet et al., “Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions,”Nat. Med. 5: 575-583 (2001).
Carr et al., “Hemodynamically-Directed Atenolol Therapy is Associated With a Blunted Rise in Maternal sFLT-1 Levels During Pregnancy,”Hypertens. Pregnancy28(1): 42-55 (2008).
Celletti et al., “Effect of Human Recombinant Vascular Endothelial Growth Factor165on Progression of Atherosclerotic Plaque,”J. Am. Coll. Cardiol. 37: 2126-2130 (2001).
Charnock-Jones et al., “Identification and Localization of Alternately Spliced mRNAs for Vascular Endothelial Growth Factor in Human Uterus and Estrogen Regulation in Endometrial Carcinoma Cell Lines,”Biol. Reprod. 48: 1120-1128 (1993).
Charnock-Jones et al., “Determination of the Circulating Levels of the Soluble Form of the VEGF-R1 (sFlt-1) in Women at High Risk of Developing Pre-Eclampsia.”J. Soc. Gynecol. Investig.10: 230 (2003).
Clark et al., “A Vascular Endothelial Growth Factor Antagonist is Produced by the Human Placenta and Released into the Maternal Circulation,”Biol. Reprod. 59: 1540-1548 (1998).
Cockell et al., “Human Placental Syncytiotrophoblast Microvillous Membranes Impair Maternal Vascular Endothelial Function,”Br. J. Obstet. Gynaecol. 104: 235-240 (1997).
Cohen et al., “Amelioration of Diabetic Nephropathy by Treatment with Monoclonal Antibodies Against Glycated Albumin,”Kidney International45: 1673-1679 (1994).
Cohen et al., “Circulating Levels of the Antiangiogenic Marker Soluble Fms-Like Tyrosine Kinase 1 Are Elevated in Women With Pregestational Diabetes and Preeclampsia: Angiogenic Markers In Preeclampsia and Preexisting Diabetes,”Diabetes Care30(2): 375-377 (2007).
Davis-Smyth et al., “The Second Immunoglobulin-Like Domain of the Vegf Tyrosine Kinase Receptor Flt-1 Determines Ligand Binding and May Initiate a Signal Transduction Cascade,”EMBO J. 15: 4919-4927 (1996).
Davis-Smyth et al., “Mapping the Charged Residues in the Second Immunoglobulin-Like Domain of the Vascular Endothelial Growth Factor/Placenta Growth Factor Receptor Flt-1 Required for Binding and Structural Stability,”J. Biol. Chem. 273: 3216-3222 (1998).
Davison et al., “New Aspects in the Pathophysiology of Preeclampsia,”J. Am. Soc. Nephrol. 15: 2440-2448 (2004).
Del-Sorbo et al., “The Synthesis of Platelet-Activating Factor Modulates Chemotaxis of Monocytes Induce

Affiliated with

Also associated with

Rating

Methods of treating pre-eclampsia and eclampsia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating pre-eclampsia and eclampsia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating pre-eclampsia and eclampsia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4151920